TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12) - Image 1

Price loading...

Springer TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)

Name: TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)
Brand: Springer

Oncology

Price History & Forecast

No Price Data Available

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

Product Specifications

Brand: Springer
Format: Hardcover
ASIN: 3319568043
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 10 July 2017
Listed Since: 09 March 2017

Barcode

No barcode data available

Springer TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)

Price History & Forecast

No Price Data Available

Price Distribution

Description

Product Specifications

Barcode

Similar Products You Might Like

TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)

Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)

Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)

Targeted Cancer Immune Therapy

Death Receptors in Cancer Therapy (Cancer Drug Discovery and Development)

Springer - Molecular Mechanisms of Tumor Cell Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance (Volume 12) (Cancer Sensitizing Agents for Chemotherapy, Volume 12)

Molecular Targets in Cancer Therapy: Understanding Cellular Pathways for Therapeutic Interventions

Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Molecular Targeting and Signal Transduction: 119 (Cancer Treatment and Research, 119)

Mechanisms of Tumor Escape from the Immune Response (Tumor Immunology and Immunotherapyseries, 1)

Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics

The Link Between Inflammation and Cancer: Wounds that do not heal: 130 (Cancer Treatment and Research, 130)

Multiple Drug Resistance in Cancer 2: Molecular, Cellular and Clinical Aspects

Multiple Drug Resistance in Cancer 2: Molecular, Cellular and Clinical Aspects

Springer - Stress Response Pathways in Cancer Textbook

Cancer Signaling: From Molecular Biology to Targeted Therapy

Cancer Immunology: A Translational Medicine Context

Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy: New Perspectives and Opportunities: 930 (Advances in Experimental Medicine and Biology, 930)

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas: 17 (Resistance to Targeted Anti-Cancer Therapeutics, 17)

Springer - Immunotherapy of Cancer: An Innovative Treatment

Molecular Oncology: Underlying Mechanisms and Translational Advancements

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)